114 related articles for article (PubMed ID: 10530414)
21. The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia.
Lowdell MW; Ray N; Craston R; Corbett T; Deane M; Prentice HG
Bone Marrow Transplant; 1997 May; 19(9):891-7. PubMed ID: 9156262
[TBL] [Abstract][Full Text] [Related]
22. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
23. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Neurology; 1996 Oct; 47(4):895-900. PubMed ID: 8857715
[TBL] [Abstract][Full Text] [Related]
24. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of roquinimex in myelodysplastic syndrome.
Rosenfeld CS; Zeigler ZR; Shadduck RK; Nilsson B
Am J Clin Oncol; 1997 Apr; 20(2):189-92. PubMed ID: 9124198
[TBL] [Abstract][Full Text] [Related]
26. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cells in peripheral blood after autologous bone marrow transplantation: a combined phenotypic and functional study.
Jorgensen H; Hokland P; Jensen T; Basse P; Hokland M
Nat Immun; 1995; 14(3):164-72. PubMed ID: 8832900
[TBL] [Abstract][Full Text] [Related]
28. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
[TBL] [Abstract][Full Text] [Related]
29. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
Ericson SG; Colby E; Welch L; Ball ED
Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells.
Lehmann D; Karussis D; Mizrachi-Koll R; Linde AS; Abramsky O
Clin Immunol Immunopathol; 1997 Nov; 85(2):202-9. PubMed ID: 9344704
[TBL] [Abstract][Full Text] [Related]
32. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulation of autoimmunity by linomide.
Karussis DM; Lehmann D; Slavin S; Kalland T; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Abramsky O
Isr J Med Sci; 1995 Jan; 31(1):38-41. PubMed ID: 7836046
[No Abstract] [Full Text] [Related]
34. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
Blaise D; Attal M; Pico JL; Reiffers J; Stoppa AM; Bellanger C; Molina L; Nedellec G; Vernant JP; Legros M; Gabus R; Huguet F; Brandely M; Hercend T; Olive D; Maraninchi D
Leuk Lymphoma; 1997 May; 25(5-6):469-78. PubMed ID: 9250817
[TBL] [Abstract][Full Text] [Related]
35. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
36. Generation of LAK cells in vitro in patients with acute leukemia.
Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
[TBL] [Abstract][Full Text] [Related]
37. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.
Gross DJ; Weiss L; Reibstein I; Hedlund G; Dahlén E; Rapoport MJ; Slavin S
Int Immunopharmacol; 2001 Jun; 1(6):1131-9. PubMed ID: 11407307
[TBL] [Abstract][Full Text] [Related]
38. Lymphokine-activated cytotoxicity in peripheral blood mononuclear cells of severely immunocompromised HIV-infected patients.
Forthal DN; Landucci G; Robinson WE
Scand J Immunol; 1997 Jan; 45(1):91-5. PubMed ID: 9010505
[TBL] [Abstract][Full Text] [Related]
39. Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report.
Tzeng CH; Chuang MW; Wang SY; Hsieh RK; Liu CJ; Fan S; Chen PM
Proc Natl Sci Counc Repub China B; 1990 Jan; 14(1):47-53. PubMed ID: 2381997
[TBL] [Abstract][Full Text] [Related]
40. Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Wahlin A; Brinch L; Hörnsten P; Evensen SA; Oberg G; Simonsson B; Hedenus M
Eur J Haematol; 1997 Apr; 58(4):233-40. PubMed ID: 9186533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
